Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
June 30 2023 - 7:33AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
June
30, 2023
Commission
File Number 001-14978
SMITH & NEPHEW plc
(Registrant's
name)
Building 5, Croxley Park,
Hatters Lane, Watford, Hertfordshire, WD18 8YE,
England
(Address
of registrant's principal executive offices)
[Indicate
by check mark whether the registrant files or will file
annual
reports
under cover Form 20-F or Form 40-F.]
Form
20-F
X
Form 40-F
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(1).]
Yes
No X
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(7).]
Yes
No X
---
---
[Indicate
by check mark whether by furnishing the information
contained
in this
Form, the registrant is also thereby furnishing information to
the
Commission
pursuant to Rule 12g3-2 (b) under the Securities Exchange Act
of
1934.]
Yes
No X
---
---
If
"Yes" is marked, indicate below the file number assigned to
the
registrant
in connection with Rule 12g3-2 (b) : 82- n/a.
Smith & Nephew plc - Director Declaration
30 June 2023
In accordance with Listing Rule 9.6.14, Smith & Nephew plc (the
"Company") announces that Angie Risley, an Independent
Non-Executive Director and Chair of the Remuneration Committee of
the Company, is to be appointed to the board of InterContinental
Hotels Group PLC as a non-executive director effective from 1
September 2023 and as Chair of their Remuneration Committee
effective from 1 January 2024.
Enquiries
Investors / Analysts
Andrew Swift
Smith+Nephew
|
+44 (0) 1923 477433
|
Media
Charles Reynolds
Smith+Nephew
|
+44 (0) 1923 477314
|
|
|
About Smith+Nephew
Smith+Nephew is a portfolio medical technology company that exists
to restore people's bodies and their self-belief by using
technology to take the limits off living. We call this purpose
'Life Unlimited'. Our 18,000 employees deliver this mission every
day, making a difference to patients' lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
franchises of Orthopaedics, Sports Medicine & ENT and Advanced
Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100
countries, and generated annual sales of $5.2 billion in
2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN,
NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer
to Smith & Nephew plc and its consolidated subsidiaries,
unless the context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and
follow us on Twitter, LinkedIn, Instagram or Facebook.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Smith
& Nephew Plc
(Registrant)
Date: June
30, 2023
By: /s/
Helen Barraclough
-----------------
Helen
Barraclough
Company
Secretary
Smith and Nephew (PK) (USOTC:SNNUF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Smith and Nephew (PK) (USOTC:SNNUF)
Historical Stock Chart
From Aug 2023 to Aug 2024